Summary by Moomoo AI
On April 25, 2024, Pfizer Inc. held its Annual Meeting of Shareholders, where several key proposals were voted upon. The nominees for Pfizer's Board of Directors were elected to serve until the next annual meeting, with votes for each nominee ranging from 3,416,127,786 to 3,641,520,694, and varying amounts of votes against and abstentions. Additionally, the selection of KPMG LLP as the company's independent registered public accounting firm for the fiscal year 2024 was ratified with a significant majority of 4,315,675,552 votes for approval. Shareholders also approved the Amended and Restated Pfizer Inc. 2019 Stock Plan and, on an advisory basis, the compensation of the Company's Named Executive Officers. However, shareholder proposals to Adopt an Independent Board Chair Policy, Publish a Congruency Report on Political, Lobbying, Electioneering Expenditures, and Publish a Report on Corporate Contributions were not approved. One proposal to Amend the Director Resignation Process was withdrawn and not presented at the meeting. The report was officially signed by Margaret M. Madden, Senior Vice President and Corporate Secretary, on April 29, 2024.